YOUR PARTNER IN ELEVATING SCIENCE
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples.
Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE.
Learn about the new BioIVT!
BioIVT Corporate Video
VIEW OUR PRODUCTS AND SERVICES
BioIVT is a worldwide provider of human and animal biological specimens and value-added services to pharmaceutical, biotechnology, diagnostic, contract research organizations (CRO), academic and government institutions.
Looking for a Product or Service?
Our new site has over 400 individual product pages featuring the complete capabilities of BioIVT.
Visit our Request A Quote page to learn how to find your product or service of interest.
FROM THE BLOG
The 22nd North American ISSX meeting was held this year in Montreal where scientists joined together to discuss issues in drug development. Hot topics included transporters, pharmacogenomics, and antibody drug conjugates (ADCs). The transporter session included lectures on kidney and hepatic transporters and potential association with drug-induced liver injury (DILI). BioIVT announced its acquisition of… Read more »
Read More >
